Mogamulizumab (KW-0761) is a monoclonal antibody targeting T cell CC chemokine receptor 4. It exhibits anticancer activity by eliminating tumor cells through antibody-dependent cytotoxicity (ADCC) and can be used in the study of cancer, adult T-cell leukemia/lymphoma (ATLL), and cutaneous T-cell lymphoma (CTCL).

In the presence of PBMCs, Mogamulizumab (10 μg/mL, 24 h) induces ADCC activity against CCR4-positive cell lines (SNT8, SNT16, SNK6, and KAI3)[2].
In PBMCs from patients with HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP), Mogamulizumab (10 μg/mL, 3 days) reduces the human T-lymphotropic virus type 1 (HTLV-1) proviral load and inhibits spontaneous proliferation[3].
Cultured PBMCs from patients with HAM/TSP treated with Mogamulizumab (1 μg/mL, 5 days) eliminate CD4+CCR4+ T cells[3].

In a murine xenograft model, Mogamulizumab (1 mg/kg, i.p., twice per week for 4 weeks) inhibits the growth of EBV-positive NK-cell lymphomas when combined with PBMC transplantation[2].
In a canine bladder cancer-engrafted mouse model, Mogamulizumab (0.1 mg/kg, i.v., every other day) combined with canine PBMCs (administered every fourth day) inhibits tumor growth[4].
Mogamulizumab (0.01-1 mg/kg, i.v.) reduces circulating CD4+CCR4+ T cells in dogs, with no observed adverse effects[4].